Ovid Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 19, 2021 / 01:10PM GMT
Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Good morning, everyone. I'm Brian Abrahams, senior biotech analyst here at RBC Capital Markets, and welcome again to day 2 of our healthcare conference.

Our next presenting company is Ovid Therapeutics, represented by their CEO and Chairman of the Board, Jeremy Levin. Jeremy thanks again for joining us.

Jeremy Max Levin - Ovid Therapeutics Inc. - Chairman & CEO

Brian, thanks a lot. Pleasure being here with you. Nice to see you at least on video. It'd be fun to see you face to face.

Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Sure, would, hopefully soon.

Questions and Answers:

Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology Analyst

So a lot going on at Ovid these days. You recently closed your amended deal with Takeda. Can you maybe talk a little bit more about that and
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot